Clinical trial NCT01091571: The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia
Official title: The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Endotoxemia
Keywords: Adenosine
Endotoxin
Innate Immunity
Dipyridamole
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2010-03-24
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: During sepsis and septic shock the immune response can be overwhelming leading to excessive tissue damage, organ failure and death. Ideally, the inflammatory response is modulated leading to both adequate protection to invading pathogens as well as limitation of an exuberant immune response. In the last few years adenosine is proposed to have a central role in the modulation of inflammation. In unfavorable conditions such as hypoxia, ischemia or inflammation adenosine is quickly up-regulated; with concentrations up to tenfold in septic patients. Many animal studies have shown that adenosine is able to attenuate the inflammatory response and decrease mortality rates. Therefore, pharmacological elevation of the adenosine concentration is an potential target to attenuate inflammation and limit organ injury. Dipyridamole, an adenosine re-uptake inhibitor is able to increase the adenosine concentration and limit ischemia-reperfusion injury. In order to study the effects of dipyridamole on the inflammatory response we aim to use the so called human endotoxemia model. This model permits elucidation of key players in the immune response to a gram negative stimulus in vivo, therefore serving as a useful tool to investigate potential novel therapeutic strategies in a standardized setting.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 and ≤ 35 years
* Male
* Healthy

Exclusion Criteria:

* Use of any medication.
* History of allergic reaction to dipyridamole
* Bleeding disorder.
* Smoking.
* Previous spontaneous vagal collapse.
* History, signs or symptoms of cardiovascular disease.
* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.
* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90).
* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50).
* Renal impairment (defined as plasma creatinin \>120 μmol/l).
* Liver enzyme abnormalities or positive hepatitis serology.
* Positive HIV serology or any other obvious disease associated with immune deficiency.
* Febrile illness in the week before the LPS challenge.
* Participation in another drug trial or donation of blood 3 months prior to the planned LPS challenge.

Primary outcomes:
measure: Circulating cytokines
timeFrame: 24 hours after LPS administration
Secondary outcomes:
measure: Hemodynamics
timeFrame: 24 hours after LPS administration
measure: Sensitivity to norepinephrine
timeFrame: 24 hrs after LPS administration
measure: Endothelial-dependent and independent vasorelaxation
timeFrame: 24 hours after LPS administration
measure: Markers of endothelial damage and circulating endothelial cells
timeFrame: 24 hrs after LPS administration
measure: Urinary excretion of markers of renal injury
timeFrame: 24 hrs after LPS administration
measure: Adenosine and related nucleotide concentrations
timeFrame: 24 hrs after LPS administration
measure: Additional blood samples will be drawn for genetic testing and measurement of: mRNA and proteins part of the adenosine metabolism
timeFrame: 24 hours after LPS administration
measure: Oxydative stress
timeFrame: 24 hours after LPS administration
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre
Study officials:
affiliation: Radboud University Medical Center
name: Bart P Ramakers, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ramakers BP, Riksen NP, Stal TH, Heemskerk S, van den Broek P, Peters WH, van der Hoeven JG, Smits P, Pickkers P. Dipyridamole augments the antiinflammatory response during human endotoxemia. Crit Care. 2011;15(6):R289. doi: 10.1186/cc10576. Epub 2011 Nov 30.